Moscow - Saba:
Russian scientists from Tomsk State University in Russia have successfully created and tested the first Russian compound for the diagnosis and treatment of prostate cancer. Data from the first phase of experimental clinical trials confirmed the tolerability and safety of therapeutic and diagnostic drugs with the new molecule.
According to the World Health Organization, prostate cancer is the second most commonly diagnosed form of cancer worldwide, with approximately one in eight men being diagnosed with it in their lifetime.
As part of the modern approach to combating oncology, scientists are working to develop drugs suitable for the diagnosis and treatment of cancers. To date, only two therapeutic diagnostic molecules have been created in the world: one for the treatment and diagnosis of prostate cancer, and the other for the treatment of neuroendocrine tumors. Both are patented and produced abroad.
Russian scientists from Tomsk State University in Russia have successfully created and tested the first Russian compound for the diagnosis and treatment of prostate cancer. Data from the first phase of experimental clinical trials confirmed the tolerability and safety of therapeutic and diagnostic drugs with the new molecule.
According to the World Health Organization, prostate cancer is the second most commonly diagnosed form of cancer worldwide, with approximately one in eight men being diagnosed with it in their lifetime.
As part of the modern approach to combating oncology, scientists are working to develop drugs suitable for the diagnosis and treatment of cancers. To date, only two therapeutic diagnostic molecules have been created in the world: one for the treatment and diagnosis of prostate cancer, and the other for the treatment of neuroendocrine tumors. Both are patented and produced abroad.